David Rubin to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications David Rubin has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.705
-
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflamm Bowel Dis. 2026 May 01; 32(5):954-962.
Score: 0.224
-
Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies. Clin Gastroenterol Hepatol. 2026 Oct; 24(10):2783-2795.
Score: 0.221
-
Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):17-21.
Score: 0.162
-
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 08; 12(1).
Score: 0.051
-
Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterol J. 2023 10; 11(8):797-806.
Score: 0.047